Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

Italian Ministries Tackle Contentious Gender Dysphoria in Minors with Joint Discussion and Evidence-Based Guidelines

The Ministry of Health and the Ministry of Family have recently initiated a joint discussion on gender dysphoria in minors, specifically focusing on the use of triptorelin, a puberty blocking drug. This discussion is being led by Ministers Orazio Schillaci and Eugenia Roccella. A group of experts will work together to develop new guidelines based on a review of scientific literature and experiences from other countries that are reevaluating their positions after widespread use of these drugs.

The two ministries have released a statement announcing this initiative and summarizing the work they have done so far on gender dysphoria and the use of blockers. This effort follows a hearing with scientific societies involved in the issue of gender dysphoria in adolescents and a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of gender dysphoria in minors. In addition, the ministries are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This collaborative effort represents a proactive approach to addressing the complex issue of gender dysphoria in minors, with a focus on evidence-based guidelines and best practices. Stay tuned for updates as the group continues its work to develop specific guidelines for this important issue.

Leave a Reply

Elon Musk Amazes Again: Brain Chip Restores Sight for Blind Monkeys Previous post Musk Unveils Brain Chip That Could Cure Blindness in Monkeys: The Future of Medical Technology?
Trump’s bond break episode | The Hill Next post Trump Wins Legal Respite from Seizure of Properties in New York as Appeals Panel Halts Enforcement of Bond Judgment